Jeremy Bastid
18 December 2020
Professor Martine Bagot and Professor Armand Bensussan are rewarded for their research on the development of a targeted therapy, lacutamab, a monoclonal antibody targeting the tumor antigen KIR3DL2 for the treatment of patients with advanced, refractory and relapsed T cell lymphomas, particularly erythrodermic cutaneous T cell lymphomas. The Galien Prize here rewards two decades of research.
17 December 2020
Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.
15 December 2020
From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !
16 October 2020
1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. Download abstract.
